{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000004","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.577449+00:00","generated_at":"2026-05-26T23:10:40.957301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline","bullets":["Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).","Full year 2024 revenue $9.7B (-2% YoY); non-GAAP EPS $16.47 (+12% YoY).","LEQEMBI global in-market sales ~$87M; SKYCLARYS revenue ~$102M, patient count nearly doubled vs end 2023.","Regulatory milestones: LEQEMBI subcutaneous BLA accepted (PDUFA Aug 31, 2025); nusinersen higher dose filings accepted (PDUFA Sep 22, 2025).","FY2025 guidance: non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit % at constant currency."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000004","json":"https://secwatch.observer/filing/0000875045-25-000004.json","markdown":"https://secwatch.observer/filing/0000875045-25-000004.md","text":"https://secwatch.observer/filing/0000875045-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/0000875045-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/biib-20250212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:10:40.957301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}